Article

ctDNA detection by personalised assays in early-stage NSCLC

2021-06-03

Abstract excerpt

Blood-based assays have shown increasing ability to detect circulating tumour DNA (ctDNA) in patients with early-stage cancer. However, detection of ctDNA in patients with non-small cell lung cancer (NSCLC) has continued to prove challenging. We performed retrospective analysis to quantify ctDNA levels in a cohort of 100 patients with early-stage NSCLC prior to treatment with curative intent enrolled in the LUCID...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6a0adcf3-76d1-5b82-b8dd-8331e696abdd
DOI: 10.1101/2021.06.01.21258171

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ctDNA detection by personalised assays in early-stage NSCLCDOI 10.1101/2021.06.01.21258171Read

Detection of trace levels of circulating tumour DNA in early stage non-small cell lung cancerSemantic proximity Read

Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.Semantic proximity Read

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancerSemantic proximity Read

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesSemantic proximity Read

The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC).Semantic proximity Read

Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.Semantic proximity Read

Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.Semantic proximity Read

Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and StagesSemantic proximity Read

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read

Revolutionizing Non-Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma.Semantic proximity Read